Acumen sinks after Alzheimer's drug fails mid-stage study
30/10/2026 11:56
BUZZ-Acumen sinks after Alzheimer's drug fails mid-stage study ** Shares of Acumen Pharmaceuticals ABOS.O plunge 78.2% to $0.50 premarket
** The biotech firm says its experimental Alzheimer's disease drug sabirnetug failed the main goal of a mid-stage study, showing no meaningful benefit in slowing memory and functional decline versus placebo
** Co says key secondary measures, including CDR-SB, also failed to reach statistical significance
** Drug reduced amyloid plaque levels in the brain, but that did not translate into clinical benefit
** Co plans to stop development of sabirnetug, end the study's extension phase and implement cash-conservation measures
** As of last close, stock up ~9% YTD
(Reporting by Sahil Pandey in Bengaluru)